Dr. Califf Returns To US FDA: What To Do First?
Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.
You may also be interested in...
US FDA Still Hasn’t Decided Who Will Be Final Arbiter On Approval Status For Covis’ Makena
With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.
US FDA Elevates Controlled Substances Coordinator To New Deputy CDER Director Role
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.
US FDA Commissioner Califf Expects To Leave Post Following 2024 Elections
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.